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TreNds iN seCoNdary Care CosTs for TreaTmeNT of Head aNd NeCk 
CaNCer iN eNglaNd
Keeping S.T.1, Naylor N.R.1, Tempest M.J.2, Stephens S.2, Carroll S.M.1
1Sanofi Pasteur MSD, Maidenhead, UK, 2Pharmerit Ltd, York, UK
Objectives: Encompassing a group of cancers originating from the upper aero-
digestive tract, head and neck cancers are ranked in the top ten for both inci-
dence and mortality among all malignancies globally. This study aimed to estimate 
trends in total secondary care costs associated with the treatment of head and 
neck cancers in England from 2006/2007 to 2010/2011. MethOds: Data on inpa-
tient and outpatient activity associated with oropharyngeal, oral cavity and laryn-
geal cancer was extracted from the Hospital Episode Statistics (HES) database. 
After grouping inpatient episodes into spells, a single Healthcare Resource Group 
(HRG) was derived for each and then cross-referenced with the National Tariff 
2010/11 to estimate the associated cost. For specific types of therapy, including 
chemotherapy and radiotherapy, HRG definitions were cross-referenced with the 
National Reference Costs for the latest available year and inflated using the PCI 
index. Outpatient costs were estimated by grouping consultations by treatment 
speciality. Results: The total cost of treatment for all cancers over the entire 
period was estimated to be around £309 million, at 2011 prices. Inpatient care 
covered by bundled HRGs accounted for over 90% of this cost, at £280 million. Total 
costs due to oropharyngeal cancer were slightly higher than those estimated for 
laryngeal and oral cancer, costing £115 million (37.06%), £96 million (31.15%) and 
£98 million (31.79%) respectively. There was, generally, an increasing trend in the 
secondary care burden of all three cancers. Annual costs and patient numbers 
increased the most for oropharyngeal cancer, with annual inpatient costs increas-
ing from £16,576,046 in 2006/07 to £28,467,016 in 2010/11. cOnclusiOns: This 
study indicates that there is a significant, and increasing, health and economic 
burden associated with head and neck cancers in England, highlighting the need 
for preventative programmes.
PCN84
eCoNomiC BurdeN of CHemoTHeraPy relaTed ToxiCiTies iN THird liNe 
meTasTaTiC BreasT CaNCer PaTieNTs
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Objectives: During chemotherapy, a majority of patients experience treatment-
related adverse-events (TEAEs). However, the number of patients requiring treat-
ment and/or hospitalization (T&H) for managing TEAEs is significantly lower. The 
objective of this study was to evaluate economic burden of TEAEs in third line 
Metastatic Breast Cancer (MBC) patients. MethOds: A post-hoc analysis was con-
ducted on Phase 3 clinical trial of eribulin vs. Treatment of Physician’s Choice (TPC) 
in MBC patients with two prior chemotherapy regimens including anthracycline and 
taxane. TPC included capecitabine, gemcitabine, vinorelbine, docetaxel and pacli-
taxel. Grade 3&4 TEAEs which were observed in ≥ 5% of patients were considered. 
Patients who required T&H for managing TEAEs were further studied. Duration and 
costs associated with T&H were obtained from a micro-costing study where UK-NHS 
tariffs for each cost unit were applied. TEAE clinical trial frequency data for each 
treatment were annualized prior to cost evaluation, based on treatment duration 
(113 days for eribulin and 68 days for TPC patients). Results: Only a small propor-
tion of patients who experienced TEAEs required T&H. The frequencies of TEAEs 
experienced vs. TEAEs that required T&H for most commonly observed TEAEs were 
as follows: neutropenia (Eribulin: 45.2% vs. 14.5%; TPC: 21.1% vs. 5.3%), leukopenia 
(Eribulin: 13.9% vs 4.2%; TPC: 5.7% vs. 1.6%), peripheral-neuropathy (Eribulin: 8.2% 
vs. 3.8%; TPC: 2.0% vs. 0.4%) and asthenia/fatigue (Eribulin: 8.8% vs. 1.6%; TPC: 10.1% 
vs. 2.0%). Monthly TEAEs requiring T&H rates were Eribulin: 19.83%, TPC: 23.67%. 
Average annual costs for management of TEAEs were £2,621 for eribulin vs. £2,740 
for TPC patients. cOnclusiOns: Economic burden of toxicities in MBC patients 
may be lower than expected as very few TEAEs require T&H. This study may have 
led to omission of rare but costly AEs because of the patient selection criteria used. 
Using individual treatments as comparators instead of TPC may have brought addi-
tional clarity to the results. Further research is warranted to validate the findings.
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intROductiOn: Lung cancer is a highly prevalent condition with non-small 
cell lung cancer (NSCLC) representing ~80%. Given its high prevalence and poor 
survival rates, it is important to understand costs associated with NSCLC treat-
ment. Objectives: To carry out a study similar to the study by Ramsey (2008) in 
three European countries: France, Germany and UK. MethOds: Three similar 
administrative databases were accessed: Hospital Episode Statistics (England), 
Gesundheitsforen Leipzig (Germany), French Hospital Discharge system (France), 
using ICD-9/10 codes and treatment/surgery algorithms to identify NSCLC patients. 
An incidence population of NSCLC patients was obtained using an index year (rang-
ing from 2007-2008), ensuring the absence of prior lung cancer (12-months). Data 
were extracted on treatment information, patient characteristics and disease stag-
ing. Average NSCLC treatments were estimated by age and severity. For England 
20,081 patients were identified, for France, 15,061, for Germany, 1,038. Results: 
In-patient length of stay was 8.9, 8.7 and 10.1 days for France, England, Germany 
respectively for the first year. Hospital in-patient costs in the first year amounted 
to € 11,667, € 11,363, € 5,985 for France, Germany and England respectively. In year 
two these were € 5,916 (France), € 6,568 (Germany) and € 1,156 (England). Hospital out-
patient costs were in year 1 and 2: € 2,313 - € 676 (France); € 1,925 - € 1,766 (Germany); 
€ 1,209 - € 834 (England). Medicine costs in year 1 and 2 amounted to: € 3,542 - € 321 
(France); € 4,488 - € 3,805 (Germany); € 8,593 yr1 only (England). Other costs reported 
Objectives: To examine the economic burden and health care utilizations 
of patients diagnosed with pancreatic cancer in the U. S. veteran popula-
tion. MethOds: A retrospective database analysis was performed using Veterans 
Health Administration Medical SAS data from 01OCT2007 through 30SEP2012. 
Patients diagnosed with pancreatic cancer were identified using International 
Classification of Disease 9thRevision Clinical Modification (ICD-9-CM) code 157. 
The first diagnosis date was defined as the index date. A group of patients with 
similar age, region, gender and index year but without a pancreatic cancer diag-
nosis were identified as the comparison group and matched by baseline Charlson 
Comorbidity Index scores. One year of continuous health plan enrollment was 
required before and after the index date for both groups. Study outcomes, includ-
ing health care costs and utilizations, were compared between pancreatic cancer 
and comparator groups using 1: 1 propensity score matching (PSM). Results: A 
total of 10,894 patients were identified for the pancreatic cancer and comparison 
cohorts. After applying a 1: 1 PSM, 3,671 patients were matched from each cohort, 
and the baseline characteristics were proportionate. Pancreatic cancer patients 
were more likely to have higher health care resource utilizations, including inpa-
tient admissions (38.03% vs. 2.18%, p< 0.0001), emergency room (ER) (30.67% vs. 
5.48%, p< 0.0001), physician office visits (98.39% vs. 57.91%, p< 0.0001) and pre-
scription fills (83.55% vs. 62.82%, p< 0.0001). Risk-adjusted health care costs were 
also higher for pancreatic cancer patients, including inpatient ($18,079 vs. $442, 
p< 0.0001), ER ($330 vs. $46, p< 0.0001), physician office ($5,600 vs. $1,106, p< 0.0001) 
and pharmacy costs ($2,244 vs. $321, p< 0.0001), resulting in higher total costs 
($26,503 vs. $1,977, p< 0.0001) relative to the comparator cohort. cOnclusiOns: 
During a period of 12 months, VHA patients diagnosed with pancreatic cancer 
reported higher health care resource utilization and costs than their matched 
controls.
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a sysTemaTiC liTeraTure review of THe eCoNomiC BurdeN iN mulTiPle 
myeloma
Rizzo M.1, Xu Y.2, Panjabi S.3, Iheanacho I.1
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Objectives: To explore the resource use and costs for multiple myeloma (MM) 
in a systematic literature review. MethOds: We searched MEDLINE, Embase, the 
Cochrane Library, and EconLit for English-language studies published from January 1, 
2003 to May 16, 2013 that evaluated resource use and costs related to MM, includ-
ing relapsed or relapsed and refractory MM (R/RRMM). These studies underwent 
data abstraction and qualitative synthesis. Results: Thirteen primary studies in 
the US (n= 5), UK (n= 1), US and UK (n= 1), The Netherlands (n= 2), France (n= 1), Italy 
(n= 1), Sweden (n= 1), and Switzerland (n= 1) met the inclusion criteria. Three studies 
were in newly-diagnosed MM patients, one in newly-diagnosed and previously-
treated patients, and nine in R/RRMM. The key cost drivers in R/RMM (as percentages 
of total costs) were medications (32% to 66%), hospitalisations (15% to 35%), and 
adverse events/complications/comorbidities (6% to 42%). Among treatment-related 
adverse events in MM, neutropenia was the main cost driver, accounting for at 
least two-thirds of total costs for managing such events, followed by thrombocyto-
penia, anaemia, and infections. In addition, metastatic bone disease significantly 
increased direct treatment costs (+$57,720 per patient; 2004 USD) and accounted 
for 17% (€ 6,937 per patient; 2002 € ) of total MM treatment costs. Also, patients with 
progressive disease incurred costs over three times those in patients without disease 
progression after initial treatment ($837 vs. $237 PPPM [2010 USD]). cOnclusiOns: 
The primary drivers of MM management costs are medication, hospitalisations, and 
adverse events. Neutropenia, skeletal complications and progressive disease are also 
especially costly in MM. This evidence highlights the need for effective therapies 
with improved tolerability profiles that delay progression across a broad range of 
patients with and without comorbidities.
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exPloriNg THe usefulNess of soCial media aNd PaTieNT forums iN 
ideNTifyiNg iNdireCT CosTs of a disease
Chalkiadaki C., Martin A.
Evidera, London, UK
Objectives: The objective of this study was to assess the breadth and usefulness of 
information available in social media and patient-specific forums on indirect costs 
of a disease. MethOds: Internet searches of general social media and patient-spe-
cific forums were performed to identify sources of information on the indirect costs 
of breast cancer and schizophrenia. Results: Searches of general social media sites 
mainly resulted in posts related to available treatments, health awareness cam-
paigns, non-patient opinions and news articles, as well as irrelevant, often malicious 
posts, such as direct insults to schizophrenic patients. Fewer, but lengthier, posts 
were identified on patient forums, which could be an effective way of identifying 
indirect costs of the diseases. Such costs include time spent off work by the patient 
and their caregivers, delays in restoring independence such as being able to drive, 
and non-medical items used by women on chemotherapy. Breast cancer appears to 
be better represented than schizophrenia, possibly because patients with mental 
health problems face social stigma and thus don’t communicate their struggle as 
openly. Topics of conversation across forums include adverse treatment events and 
their associated costs, as well as other costs incurred by the patients due to their 
deteriorating health and quality of life. cOnclusiOns: This study looked at avail-
able information on the economic burden of breast cancer and schizophrenia on its 
patients and found that general social media appear to be less useful than patient 
forums. Depending on the disease being researched, different kinds of information 
become available and prove to be useful in drawing conclusions about the indirect 
costs of an illness. The breast cancer community appears to be better represented 
and more vocal about resource use associated with the disease or treatment than 
the schizophrenia community. The perspective of caregivers is less represented in 
breast cancer than schizophrenia.
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health-insured patients: from the 4th day of disability, the Instituto Mexicano del 
Seguro Social covers 60% of wages, 2) Private health-insured: economical loss of 
private beneficiaries is a 20% co-pay plus daily average income lost. 3) No-health-
insurance: Medical costs and absenteeism represent the economical loss. Costs are 
expressed in 2014 USD (1USD= 13MXN). Morbidity cases were extracted from pub-
lished data by National Institute of Public Health and used to calculate a weighted 
average of economical losses for each scenario. Results: The distribution of 
people with smoking-related disease (AMI, COPD and LC) was 25.0%, 65.4% and 
9.6%, respectively. Patients in scenario 1) 2) and 3) spend/lose an average of $446.6, 
$8,448.2 and $37,384.95 per year, respectively (medical costs are the drivers of the 
economic resources lost by not-insured population). Average illness expense derived 
from tobacco consumption regarding the proportion of people in each scenario 
was $13,917 yearly (local per capita GDP is $9,749). Regardless of health-insurance 
status, LC is the most expensive disease ($39,564.26), followed by AMI and COPD 
($14,337.06 and $10,109.32, respectively). cOnclusiOns: The study showed that in 
the long run smokers incur significant economic losses even if they have medical 
insurance. Costs increases to people that do not have any insurance.
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CosT ComParisoN amoNg firsT liNe moNoCloNal aNTiBodies-Based 
oNCology TreaTmeNT ProToCols
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Objectives: To assess and compare the costs of first-line monoclonal antibodies 
(mABs) treatment protocols in breast cancer, non-Hodgkin lymphoma and colo-
rectal carcinoma in South-Εastern Europe. MethOds: A retrospective, bottom-up 
case series study design was implemented with one-year time horizon and payer’s 
perspective. The study sample size was 265 patients (breast cancer, N= 137, colorec-
tal cancer, N= 44, and non-Hodgkin lymphoma, N= 84) while treatment protocols 
included adjuvant mAbs: trastuzumab (N= 137), bevacizumab (N= 28), cetuximab 
(N= 16) and rituximab (N= 84). ICD-10 related, direct medical and lost productivity 
costs (€ ) across treatment groups during 2010-2013. Results: The average length 
of observation was 128±97 days per patient. Total mean direct and indirect costs 
of care were: trastuzumab breast cancer group € 17,740; bevacizumab colorectal 
carcinoma group € 8,775; cetuximab colorectal carcinoma group € 27,181 and rituxi-
mab non-Hodgkin lymphoma group € 19,431. An average mAbs-treated patient 
incurred € 17,897 costs of medical care. The total combined budget of these 265 
patients was € 4,742,775. cOnclusiOns: The use of mAbs strongly correlated with 
high costs in first-line cancer medical care and dominated other cost domains. 
Cetuximab-based treatment protocol in colorectal carcinoma patients was sub-
stantially more expensive compared to trastuzumab (C50); bevacizumab (C20) 
and rituximab (C80) alternatives. Extremely high costs of mAbs are the key-issue 
for Eastern European policy makers by crossing the upper limits of affordability 
in middle-income economies.
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use PaTTerNs aNd CosTs of isolaTed limB PerfusioN aNd iNfusioN iN 
THe TreaTmeNT of regioNally meTasTaTiC melaNoma: a reTrosPeCTive 
daTaBase aNalysis
Ma Q., Zhao Z., Barber B., Shilkrut M.
Amgen Inc, Thousand Oaks, CA, USA
Objectives: Isolated limb perfusion and infusion (ILP/ILI) are therapies for region-
ally metastatic melanoma where high doses of anticancer drugs are delivered 
directly into the circulation of an affected limb, while minimizing systemic drug 
exposure. This procedure can lead to high response rates but without proven ben-
efits to overall survival. It is recommended by ESMO and NCCN guidelines as a treat-
ment option for patients with stage III unresectable metastatic melanoma. However, 
limited information is available on its use pattern and costs in the literature. This 
study was to examine patterns of ILP/ILI use and associated costs in patients with 
melanoma in the US. MethOds: This is a retrospective, observational study using 
large administrative claims from the MarketScan® databases. Patients who under-
went ILP/ILI (CPT-4: 36823) with diagnosis of melanoma (ICD-9-CM: 172. xx, V10.82) 
between 1/1/2002 and 3/31/2013 were included. Patient characteristics, use patterns, 
hospital length of stay, and costs (2013 US $) of ILP/ILI were assessed. Results: 
A total of 113 patients met the study criteria and were included in the analysis. The 
mean age was 62.1 years (standard deviation [SD] 14.1); 39.8% were male. The mean 
baseline Charlson’s comorbidity index was 0.24 and 36.4% of patients were Medicare 
beneficiaries. Overall, 86.4% of patients had melanoma in the lower limb, 12.7% in 
the upper limb, and 0.9% in both upper and lower limbs; 59.3% had lymph node 
metastasis and 56.8% had skin metastasis. Four patients (3.5%) underwent multiple 
ILP/ILI procedures. The mean (±SD) hospital length of stay was 5.6 (± 3.5) days and 
the mean (±SD) cost was $35,898 (± $26,492) per ILP/ILI procedure. cOnclusiOns: 
The use of isolated limb perfusion and infusion was associated with relatively long 
hospital stay and high cost. The results of this study may provide source data for 
economic evaluations of treatment options for regionally metastatic melanoma.
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a guideliNe-Based esTimaTe of HealTH Care resourCe use aNd CosT of 
meTasTaTiC uNreseCTaBle osTeosarComa
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Objectives: To estimate the resource use and costs a health plan can anticipate 
during the diagnosis, treatment, and surveillance of a patient with metastatic unre-
for France and Germany in year 1 and 2, were € 502 - € 126 for France; € 1,429 - € 1,156 
for Germany. Total costs reached € 18,024 (yr1), € 7,039 (yr2) France; € 19,025 (yr1), 
€ 13,295 (yr2) Germany; € 15,785 (yr1), € 1,990 (yr2) England. Two-year costs totalled 
€ 25,063 (France); € 32,500 (Germany); € 17,777 (England). Subgroup analyses showed 
higher costs for elderly patients, those with non-metastatic disease and smokers.  
cOnclusiOns: Considerable differences in average treatment costs were observed. 
In-patient costs dominate in the first year of treatment in all countries. The study 
highlights the costly nature of NSCLC.
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CosT of BesT suPPorTive Care for NoN-small Cell luNg CaNCer 
PaTieNTs – a germaN PersPeCTive
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Objectives: Best supportive care (BSC) is in general individually provided to 
patients. Thus, the scope of BSC and its costs can vary widely. Only limited 
information on BSC costs for patients with non-small cell lung cancer (NSCLC) 
exists. Aim of this research was to estimate annual BSC costs for NSCLC patients 
in Germany. MethOds: To estimate BSC costs at first a literature search in 
PubMed with the key words “best supportive care”, “cost”, “non-small cell lung 
cancer” and “economic analysis” individual and combined search terms was 
performed. International publications of economic evaluations including data 
on single cost items which could be applied to the German health care system 
were included. Additionally, data on BSC from a NSCLC patient registry (n= 193) 
and prescription data derived from a randomised controlled trial (RCT) were used 
as further references. Cost- items were extracted from each reference and finally 
applied to the German inpatient and outpatient reimbursement system. Results: 
The literature research yielded 317 records of which 3 met the inclusion crite-
ria (2= UK; 1= North America). An extrapolation of these evaluation results to the 
German health care system showed that BSC costs based on UK data ranged 
from 16,940€ to 45,426€ (North America: 31,352€ ). According to health economic 
data from an RCT annual cost for BSC amounted to 17,531€ , while data from a 
NSCLC patient registry added up to 28,070€ . The average annual costs for BSC 
were estimated at 27,864€ . cOnclusiOns: Since BSC is individually delivered 
to patients, it leads to a high variance of annual BSC costs for NSCLC patients in 
Germany. Furthermore, international economic evaluations were extrapolated 
to the German health care system. Hence, results should be interpreted with 
caution as international treatment guidelines and reimbursement schemes are 
not fully applicable to Germany. Future analyses should be based on a German 
population only.
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disTriBuTioN aNd CosTs from THe PuBliC HealTH Care PersPeCTive
Valle P.M.1, Mosegui G.B.G.2, Vianna C.1, Araujo R.L.1
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Objectives: Treatment for breast cancer is usually based on chemotherapy 
and radiotherapy, but in unsuccessful cases, mastectomy is required. In Brazil, 
mastectomies are performed as simple or radical, with lymphadenectomy. This 
study aims to relate geographic distribution, temporal trends and economic profile 
of this procedure in Brazil. MethOds: Assessments about hospital admissions 
were performed to analyze costs and geographic distribution among mastectomies 
related with breast cancer realized in Brazil, from January 2008 to December 2012. 
The data used were extracted by Brazilian Hospital Information System (SIH/SUS) 
database, according to ICD-0416120032 (simple mastectomy) and ICD-0416120024 
(radical with lymphadenectomy). Costs were estimated in 2014 Brazilian Real (BRL) 
and represents federal reimbursement values for hospitalizations (exams, drugs, 
medical procedures and fees). Results: In Brazil, the number of mastectomies 
related with breast cancer ranged from 8,687 in 2008 to 9,703 in 2012. In Southeast 
region were performed 22,977 procedures, which was the largest number per 
region, compared with 1,814 in North; 8,443 in South; 2,280 in Midwest and 10,538 
in Northwest. In São Paulo; 10,111 procedures occurred in this period, while 8 were 
performed in Amapá. Total costs with mastectomies due to breast cancer in Brazil 
during this period were 44,219,235.66 BRL. The value per patient increased about 
12,5% over the years with mean costs from 2008 to 2012 of 799.75BRL, 842.62BRL, 
845.28BRL, 878.20BRL and 870.25BRL, respectively. In 2010, the mean mortality rate 
among simple and radical mastectomies was 0,22% and increased until 0,54% in 
2012. cOnclusiOns: Geographic distribution of mastectomy due to breast cancer 
in Brazil is concentrated in Southeast region, in comparison to other regions and 
from 2008 to 2012 there was no change in this pattern. Although costs elevated, 
mortality also increased in this period.
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esTimaTioN of eCoNomiC losses resulTiNg from diseases assoCiaTed 
wiTH smokiNg iN mexiCaN iNsured aNd uNiNsured PoPulaTioN
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Objectives: Few data has been published in Mexico related to direct smoking 
costs from the consumer perspective. To estimate lost income and pocket costs 
related to smoking diseases from the perspective of Mexican families. MethOds: 
The analysis incorporated patients with public, private and no-health insurance 
from 18-65 years. Through Mexican literature review, medical costs and prevalence 
of 3 major diseases associated with tobacco consumption were identified: acute 
myocardial infarction (AMI), chronic obstructive pulmonary disease (COPD) and lung 
cancer (LC) as well as absenteeism associated to each disease. Average income was 
extracted from 2012 national income survey. Scenarios evaluated were: 1) Publicly 
